Stéphane Boissel

Stéphane Boissel

Voorzitter bij ADOCIA
57 jaar
Health Technology
Consumer Services
Commercial Services

Profiel

Stéphane Boissel currently works at SparingVision SAS, as President, Chief Executive Officer & Director from 2023, Adocia SA, as Chairman, Cottages Participations SAS, as Chairman, Transgene, Inc., as Director, Platine Pharma Services SAS, as Director, Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd., as Director, EG 427 SAS, as Director from 2021, and The French Society of Financial Analysts, as Member.
Mr. Boissel also formerly worked at Sangamo Therapeutics France SAS, as Chief Executive Officer, Genclis SA, as Chief Executive Officer from 2014 to 2015, ElsaLys Biotech SAS, as Non-Executive Chairman from 2013 to 2018, ERYTech Pharma SA, as Director from 2004 to 2009, Pharmaxon SAS, as Director, Sangamo Therapeutics, Inc., as Executive Vice President-Corporate Strategy from 2019 to 2020, Eurazeo SE, as Vice President from 1995 to 1998, Transgene SA, as Chief Financial Officer & Executive Vice President from 2010 to 2014, Innate Pharma SA, as Chief Financial Officer & Executive Vice President in 2010, Lazard Group LLC, as Vice President in 2002, France Biotech Association, as Member, PricewaterhouseCoopers France SARL, as Auditor in 1994, and Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., as Member-Supervisory Board.
Mr. Boissel received his graduate degree in 1993 from Université Paris Dauphine-PSL, undergraduate degree from the University of Lyon, and Masters Business Admin degree from The University of Chicago Booth School of Business.

Actieve functies van Stéphane Boissel

BedrijvenFunctieBegin
ADOCIA Voorzitter -
Algemeen Directeur 21-10-2020
Voorzitter -
Corporate Officer/Principal -
Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd.
Directeur/Bestuurslid -
Directeur/Bestuurslid -
Directeur/Bestuurslid -
Directeur/Bestuurslid 01-03-2021

Eerdere bekende functies van Stéphane Boissel

BedrijvenFunctieEinde
SANGAMO THERAPEUTICS, INC. Financieel Directeur/CFO 31-10-2019
░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░ ░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░ ░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Ervaring van Stéphane Boissel in detail bekijken

Opleiding van Stéphane Boissel

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

71

Eerstegraads connecties

24

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit24

Health Technology

Finance

Health Technology

Health Technology

Finance

Consumer Services

Health Technology

Commercial Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Commercial Services

Health Technology

Consumer Services

Health Services

Commercial Services

Health Technology

Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd.

Health Technology

Miscellaneous

Health Technology

  1. Beurs
  2. Insiders
  3. Stéphane Boissel
DE LAATSTE UREN | -40 %: De beste tools voorbehouden aan abonnees om de beste beleggingen van morgen te identificeren!
d
:
:
PROFITEER NU